{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:25:57Z","timestamp":1793157957237,"version":"4.5.0"},"reference-count":82,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,7,7]]},"DOI":"10.1001\/jama.2020.5493","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T15:04:07Z","timestamp":1594134247000},"page":"79","source":"Crossref","is-referenced-by-count":350,"title":["Systemic Amyloidosis Recognition, Prognosis, and Therapy"],"prefix":"10.1001","volume":"324","author":[{"given":"Morie A.","family":"Gertz","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"jrv200004r1","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/modpathol.2011.117","article-title":"Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study.","volume":"24","author":"Ueda","year":"2011","journal-title":"Mod Pathol"},{"issue":"3","key":"jrv200004r2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study.","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"issue":"3","key":"jrv200004r3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.mayocp.2019.01.023","article-title":"Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015.","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"jrv200004r4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/03007995.2017.1297930","article-title":"Disease burden of systemic light-chain amyloidosis: a systematic literature review.","volume":"33","author":"Lin","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"jrv200004r5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"issue":"7","key":"jrv200004r6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"issue":"1","key":"jrv200004r7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis.","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"jrv200004r8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment.","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"jrv200004r9","first-page":"93","article-title":"New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center\u2019s experience.","volume":"2","author":"Suhr","year":"2012","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"9","key":"jrv200004r10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur Heart J"},{"key":"jrv200004r11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/13506129.2011.574354030","article-title":"Approach to diagnosis in systemic amyloidosis: initial findings and time from symptoms onset to diagnosis (light-chain amyloidosis vs. transthyretin): problems and observations.","volume":"18","author":"Di Girolamo","year":"2011","journal-title":"Amyloid"},{"issue":"10","key":"jrv200004r12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the amyloidosis research consortium.","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"issue":"2","key":"jrv200004r13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3233\/JND-180348","article-title":"Spinal stenosis in familial transthyretin amyloidosis.","volume":"6","author":"Carr","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"16","key":"jrv200004r14","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/eurheartj\/ehz128","article-title":"Quadriceps tendon rupture in wild-type transthyretin amyloidosis (ATTRwt).","volume":"40","author":"Barge-Caballero","year":"2019","journal-title":"Eur Heart J"},{"issue":"5","key":"jrv200004r15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","article-title":"Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy.","volume":"88","author":"Cortese","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"jrv200004r16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.4103\/1319-2442.243966","article-title":"Clinical and laboratory profile of renal amyloidosis: a single-center experience.","volume":"29","author":"Engineer","year":"2018","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"2","key":"jrv200004r17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.hfc.2016.12.003","article-title":"Current concepts of cardiac amyloidosis: diagnosis, clinical management, and the need for collaboration.","volume":"13","author":"Ritts","year":"2017","journal-title":"Heart Fail Clin"},{"issue":"2","key":"jrv200004r18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"2","key":"jrv200004r19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11886-019-1094-z","article-title":"Echocardiographic findings in cardiac amyloidosis: inside two-dimensional, doppler, and strain imaging.","volume":"21","author":"Di Nunzio","year":"2019","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"jrv200004r20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/clc.22353","article-title":"Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.","volume":"38","author":"Cappelli","year":"2015","journal-title":"Clin Cardiol"},{"issue":"7","key":"jrv200004r21","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1253\/circj.CJ-16-1259","article-title":"Identification and assessment of cardiac amyloidosis by myocardial strain analysis of cardiac magnetic resonance imaging.","volume":"81","author":"Oda","year":"2017","journal-title":"Circ J"},{"issue":"2","key":"jrv200004r22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/ane.2019.139.issue-2","article-title":"Hereditary transthyretin-related amyloidosis.","volume":"139","author":"Finsterer","year":"2019","journal-title":"Acta Neurol Scand"},{"issue":"17","key":"jrv200004r23","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release.","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"jrv200004r24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.21603","article-title":"Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients.","volume":"85","author":"Thompson","year":"2010","journal-title":"Am J Hematol"},{"issue":"3","key":"jrv200004r25","first-page":"472","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing.","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"jrv200004r26","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies.","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin Chem"},{"issue":"9","key":"jrv200004r27","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/s41375-018-0209-7","article-title":"European Myeloma Network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.","volume":"32","author":"Gavriatopoulou","year":"2018","journal-title":"Leukemia"},{"issue":"24","key":"jrv200004r28","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis.","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"jrv200004r29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2017.1314959","article-title":"Amyloid in bone marrow smears in systemic light-chain amyloidosis.","volume":"24","author":"Kimmich","year":"2017","journal-title":"Amyloid"},{"issue":"1","key":"jrv200004r30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/imj.12288","article-title":"How to diagnose amyloidosis.","volume":"44","author":"Mollee","year":"2014","journal-title":"Intern Med J"},{"issue":"24","key":"jrv200004r31","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"24","key":"jrv200004r32","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"issue":"4","key":"jrv200004r33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1136\/jclinpath-2014-202722","article-title":"A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue.","volume":"68","author":"Gilbertson","year":"2015","journal-title":"J Clin Pathol"},{"issue":"6","key":"jrv200004r34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.mayocp.2017.02.016","article-title":"Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo Clinic experience.","volume":"92","author":"Kourelis","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"jrv200004r35","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.mayocp.2017.09.016","article-title":"Prevalence of monoclonal gammopathy in wild-type transthyretin amyloidosis.","volume":"92","author":"Geller","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"jrv200004r36","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.2018.205336","article-title":"Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.","volume":"104","author":"Dittrich","year":"2019","journal-title":"Haematologica"},{"issue":"18","key":"jrv200004r37","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"jrv200004r38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"jrv200004r39","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"1","key":"jrv200004r40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12872-018-0952-8","article-title":"Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers.","volume":"18","author":"Kyriakou","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"issue":"10","key":"jrv200004r41","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"jrv200004r42","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis.","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"11","key":"jrv200004r43","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"issue":"13","key":"jrv200004r44","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem cell transplantation for light chain amyloidosis: decreased early mortality over time.","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv200004r45","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41409-018-0284-4","article-title":"High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review.","volume":"54","author":"Varga","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"jrv200004r46","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1182\/blood-2015-06-648113","article-title":"Upfront CyBorD in AL amyloidosis.","volume":"126","author":"Cibeira","year":"2015","journal-title":"Blood"},{"issue":"4","key":"jrv200004r47","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.","volume":"99","author":"Palladini","year":"2014","journal-title":"Haematologica"},{"issue":"22","key":"jrv200004r48","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood.V128.22.646.646","article-title":"A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis.","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood"},{"issue":"11","key":"jrv200004r49","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1515\/cclm-2016-1024","article-title":"Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.","volume":"55","author":"Palladini","year":"2017","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"jrv200004r50","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"7","key":"jrv200004r51","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/07853890.2017.1304649","article-title":"Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition.","volume":"49","author":"Muchtar","year":"2017","journal-title":"Ann Med"},{"issue":"supplement 1","key":"jrv200004r52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1182\/blood-2019-124409","article-title":"Primary results from the phase 3 tourmaline-al1 trial of ixazomib-dexamethasone versus physician's choice of therapy in patients (Pts) with relapsed\/refractory primary systemic al amyloidosis (RRAL).","volume":"134","author":"Dispenzieri","year":"2019","journal-title":"Blood"},{"issue":"15","key":"jrv200004r53","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"issue":"12","key":"jrv200004r54","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv200004r55","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","article-title":"Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.","volume":"128","author":"Bochtler","year":"2016","journal-title":"Blood"},{"issue":"6","key":"jrv200004r57","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/bjh.2018.182.issue-6","article-title":"Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services.","volume":"182","author":"Popat","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"jrv200004r58","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"issue":"36","key":"jrv200004r61","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"jrv200004r62","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"issue":"17","key":"jrv200004r63","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1200\/JCO.2015.63.3123","article-title":"European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin m-related light chain amyloidosis.","volume":"34","author":"Sachchithanantham","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"jrv200004r64","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"key":"jrv200004r65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116424","article-title":"Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS + 7.","volume":"405","author":"Dyck","year":"2019","journal-title":"J Neurol Sci"},{"issue":"18","key":"jrv200004r66","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1182\/blood-2018-07-865857","article-title":"Beyond NEOD001 for systemic light-chain amyloidosis.","volume":"132","author":"Varga","year":"2018","journal-title":"Blood"},{"issue":"12","key":"jrv200004r67","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126526","article-title":"Predictive model of response to tafamidis in hereditary ATTR polyneuropathy.","volume":"4","author":"Monteiro","year":"2019","journal-title":"JCI Insight"},{"issue":"11","key":"jrv200004r68","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv200004r69","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy.","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"jrv200004r70","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges.","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transpl"},{"issue":"24","key":"jrv200004r71","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"jrv200004r72","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis.","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv200004r73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv200004r74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies.","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"jrv200004r75","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00277-015-2549-y","article-title":"Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis.","volume":"95","author":"Suzuki","year":"2016","journal-title":"Ann Hematol"},{"issue":"11","key":"jrv200004r76","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.hlc.2016.12.017","article-title":"The utility of 99mTc-DPD scintigraphy in the diagnosis of cardiac amyloidosis: an Australian experience.","volume":"26","author":"Moore","year":"2017","journal-title":"Heart Lung Circ"},{"issue":"5","key":"jrv200004r77","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/WCO.0000000000000476","article-title":"Familial amyloid polyneuropathy.","volume":"30","author":"Adams","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"jrv200004r78","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/(ISSN)1096-8652","article-title":"Suspected cardiac amyloidosis: endomyocardial biopsy remains the diagnostic gold-standard.","volume":"82","author":"Kristen","year":"2007","journal-title":"Am J Hematol"},{"key":"jrv200004r79","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis.","volume":"29","author":"Obici","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"10038","key":"jrv200004r80","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis.","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"jrv200004r81","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ajh.v91.10","article-title":"Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.","volume":"91","author":"Hwa","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"jrv200004r82","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/13506129.2019.1594759","article-title":"Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.","volume":"26","author":"Shen","year":"2019","journal-title":"Amyloid"},{"key":"jrv200004r60","author":"Comenzo","year":"2019"},{"key":"jrv200004r56","unstructured":"Trial of venetoclax (ABT-199) and dexamethasone for relapsed or refractory systemic AL amyloidosis. ClinicalTrials.gov identifier: NCT03000660. Updated May 3, 2019. Accessed June 9, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03000660"},{"key":"jrv200004r59","unstructured":"A study to evaluate the efficacy and safety of daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared to cybord alone in newly diagnosed systemic amyloid light-chain (AL) amyloidosis. ClinicalTrials.gov identifier: NCT03201965. Updated May 1, 2020. Accessed June 9, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03201965"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2767867\/jama_gertz_2020_rv_200004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T12:43:58Z","timestamp":1723207438000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2767867"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.5493","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}